Christiana Care Dedicates New Atrium at Wilmington Hospital to AstraZeneca

AstraZeneca continuously seeks opportunities to improve health in our local communities, including through its support of partners and programs that make a difference in the lives of patients and their families.  On Tuesday, July 22, Christiana Care Health System dedicated its new atrium at Wilmington Hospital to AstraZeneca during a special ribbon-cutting ceremony, in a show of appreciation for the company’s $1 million contribution to support the Wilmington Hospital Transformation Project, designed to advance patient and family centered care.

Ribbon Cutting

At the event, Christiana Care Health System unveiled a plaque, which will be displayed in the atrium and serves to commemorate AstraZeneca and Christiana Care’s shared commitment to improving patient health.  Joining in the celebration with Christiana Care and AstraZeneca executives and employees were government officials, including Delaware Governor Jack Markell, and other community and business leaders.

“AstraZeneca is dedicated to building strong, healthy communities across the state of Delaware and nationwide,” said Paul Hudson, president, AstraZeneca U.S. and executive vice president, North America.  “Christiana Care shares in this commitment, and we’re pleased to support the expansion of its outstanding hospital system, which supports a patient-centered culture and delivers critical health resources to our community every day.”

Atrium - back view

The skylit atrium, complete with a waterfall fountain set amid lush indoor garden beds, serves as a new main entryway for Christiana Care patients, family and employees.  It provides patients and their families with easy access to the new Wilmington Hospital Health Center, a full-service health care provider offering wellness and preventive health care visits for patients of all ages, as well as the Gateway Building, a 51,000-square-foot medical office building that allows doctors to practice onsite.  Both the Wilmington Hospital Health Center and the Gateway Building will open this fall.  The atrium also connects to Wilmington Hospital’s new outdoor Healing Garden and the First State School, one of only three hospital-based schools in the nation for students with serious illnesses.

The Wilmington Hospital Transformation Project, which includes a number of other improvements – from a new main lobby and intensive care unit, to an expanded emergency department and more – is expected to be completed in the spring of 2015.

“We are thankful to philanthropic partners like AstraZeneca for helping us transform the Wilmington Hospital campus so we can serve our neighbors in Wilmington and the surrounding region,” said Robert J. Laskowski, M.D., MBA, president and CEO, Christiana Care. “AstraZeneca’s generous investment enables us to provide more access to care and greater value for our patients.”

Industry Experts Join AZ Leaders to Discuss Value in Healthcare

How is value defined by healthcare’s many stakeholders? How can the priorities of these stakeholders be pursued to get the best result for patients? How can the U.S. healthcare system improve patient health, while lowering the cost of care?

These questions and others were explored on Monday, July 14, as AstraZeneca executives – including Paul Spittle, Vice President of Growth and Marketing; Diane Sullivan, Vice President of Market Access & Patient Strategies; and Rich Buckley, Vice President of North America Corporate Affairs – hosted a group of industry experts in Washington, D.C. for a dinner discussion about the concept of value in today’s evolving healthcare environment.


Participants represented a broad range of stakeholders, from insurance and hospital executives, to nonprofit groups, policy experts and media. Julie Rovner, Robin Toner Distinguished Fellow and Senior Correspondent for Kaiser Health News, served as moderator for the discussion.


Paul Spittle, Vice President of Growth and Marketing, AstraZeneca

Participants discussed how the definitions and perceptions of value are wide-ranging and constantly evolving (over time and through changing circumstances), making it difficult to identify effective and sustainable solutions to improve healthcare.  Despite these challenges, the group explored a number of actions that can be taken to help strengthen and preserve the quality of healthcare for patients while controlling costs — from better harnessing the power of available data and technology, to offering wellness and preventable care programs, to engaging patients in the health value discussion in a truly meaningful way.

Rich Buckley, Vice President of North America Corporate Affairs and Diane Sullivan, Vice President of Market Access & Patient Strategies, AstraZeneca

Rich Buckley, Vice President of North America Corporate Affairs and Diane Sullivan, Vice President of Market Access & Patient Strategies, AstraZeneca

The dinner was part of a series of events coordinated by National Journal LIVE, a premier events business that convenes top leaders in the Washington, D.C. area to discuss possible solutions to the country’s biggest challenges.

Senator Mikulski Visits AstraZeneca’s Frederick Manufacturing Center

14 July 2014 AstraZeneca Frederick Biotech (2)On Monday, July 14, Senator Barbara A. Mikulski, a senior member of the Senate Health, Education, Labor and Pensions (HELP) Committee, visited AstraZeneca’s Frederick Manufacturing Center in Maryland to learn more about the complex process of biologics manufacturing and the role of the facility in producing medicines used by millions of patients worldwide.

During the visit, the Senator joined AstraZeneca executives in a discussion about the importance of innovation in biotechnology, and how the company and the industry are working to make a positive impact on community health and the local economy. AstraZeneca also provided the Senator an overview of its Frederick manufacturing operations situated on a 33 acre campus and consisting of three buildings, where the company manufactures both commercial and clinical biologics. Afterward, the Senator met and mingled with employees over lunch.

14 July 2014 AstraZeneca Frederick Biotech

“In Maryland, life sciences are the life blood of our economy. Here at AstraZeneca, I heard first-hand the importance of biotech in promoting community health and supporting research, innovation and manufacturing jobs here in Frederick,” said Senator Mikulski. Mikulski 1C“I’m proud to support research and innovation jobs in Maryland’s biotech industry, keeping our state competitive in the global economy. By working to develop safe and effective treatments, we can help ensure that our nation’s health care providers have the tools they need to keep families healthy.”

AstraZeneca’s Frederick Manufacturing Center is an FDA licensed, large-scale cell culture production facility, with hundreds of thousands of square feet of administrative, production, warehouse, laboratory and utility space. The center is the largest biologics manufacturing facility within AstraZeneca’s global network and portfolio of assets, and a global industry leader in cell culture manufacturing.

The Frederick Manufacturing Center has been recognized with a number of awards, including an Economic Development Project Award from the Department of Economic Development for the City of Frederick, and a Silver Award as part of the Healthy Workplace Award Program, a joint effort among Frederick’s Regional Health System, the county Health Department, and the Chamber of Commerce, honoring businesses for their commitment to employee health and well-being.

AZ Research Presented at American Diabetes Association Meeting

By John Yee, MD, MPH, Vice President, Head of Medical Affairs, US Diabetes 

Every year, researchers come together at the American Diabetes Association (ADA) Scientific Sessions, where the latest advances in diabetes prevention, diagnosis and treatment are showcased. This year’s 74th annual Scientific Sessions, held June 13-17 in San Francisco, brought together 18,000 participants from across the U.S. and around the globe, making it the world’s largest diabetes meeting. AstraZeneca presented 43 abstracts summarizing new diabetes research, including a Phase III study on an investigational combination therapy and data that supports the safety and efficacy of approved AstraZeneca products. AstraZeneca’s portfolio of marketed products within three growing classes of non-insulin, anti-diabetes treatments was also highlighted at the meeting.

The data shared at ADA demonstrates AstraZeneca’s dedication to advancing science by continuing to evaluate the efficacy and safety of our approved medications and investigating new treatment options to help patients control the disease. We plan to extend our efforts in the fight against diabetes through our recently expanded portfolio.

In addition to highlighting our portfolio on the Session floor at ADA, our AstraZeneca team proudly participated in the ADA 5K on Sunday morning, June 15. Our employees demonstrated their collective commitment to those living with diabetes by getting moving during the ADA’s Run/Walk.


At AstraZeneca, we are proud to provide meaningful medicines that may help people living with diabetes better manage a complex disease and we are committed to showing our support.

AstraZeneca at the Cannes Lions Health Festival – Digital innovation, moving beyond the pill

By John McCarthy, VP, global commercial excellence, AstraZeneca

McCarthy, John 2012 (USLT Picture)

The first ever Cannes Lions Health Festival held in Cannes, France, June 13-14, brought together healthcare communicators and brands to discuss the sector’s current state and collaboratively forge into the future.

I presented a seminar, along with our partner DigitasLBi, on advances in digital technology that are revolutionizing the wellbeing of patients, and minimizing strain for health service providers. I spoke to how AstraZeneca’s unique patient-centric approach is enabled by rapid product prototyping, testing and learning – the DIG model.

DIG stands for Digital Innovation Group and is a collaboration between DigitasLBi and AstraZeneca. We’re a team with a broad range of skills taken from two very different industries. We came together to take on and solve some of the big challenges facing the pharmaceutical industry, from improving the way healthcare professionals work, connect and learn, to finding new ways to put patients in the driver’s seat when it comes to decisions about their health and treatment options.

The DIG model is a completely different way of working and aims to create products and services that are sustainable and that make a real difference both to doctors and to patients. I know that as DIG delivers more results through the rest of this year, we’ll see physicians and patients benefiting from our work.

John McCarthy at Cannes

I shared with the audience at Cannes the three approaches that are fundamental to success in digital innovation:

  1. Be different. It’s real easy to say. But you’ve got to be in a space that’s uncomfortable, you’ve got to free yourselves from your organization. If you want a different result, you’d better be different from the beginning.
  2. Be humble. There is humility in creating a learning environment. You have to put aside what you know. You have to be willing to listen to somebody else that has a better insight, who is more in touch with the patient, the process, the physician.
  3. Be brave. We’re in an innovative space and we fail a lot. We’re focusing on some things that we think are pretty successful to date, but we could still fail. We have another 20-25 ideas that we’ve already put on the shelf. Failure is real and, if you are still thinking in the old way it can tear you down. Or it can make you stronger.

As we further our digital innovation, we know it requires us to think differently and move from selling products to creating services that are meaningful to patients and physicians, in other words, moving beyond the pill.

It was a tremendous experience to participate and present at this global conference, while proudly representing the innovative work that AstraZeneca and DigitasLBI are advancing. These initiatives speak to AstraZeneca’s values – we are committed to helping physicians with the demands in their practices and solving problems for patients. We must put patients first – they have to be at the center of what we do. If we do this, I’m confident our work can make a truly meaningful difference.


AstraZeneca Talks Oncology with Social Media Leaders

By Rachel Humphrey, Head of Immuno-Oncology 

Today’s patient is online. Not only are patients searching for information on their personal health conditions, but they are seeking other patients who have shared in their experiences. This is especially true in the oncology space, where patients and advocates have taken to social media, helping each other locate resources and discuss the advancement of cancer research and care.

In June of 2013, through an inaugural oncology summit, we were able to learn firsthand from a diverse group of advocates about the online communities they’ve started, the information they consider most useful, and what AstraZeneca can do to help.

Continuing our efforts to give a voice to patients living with these debilitating diseases, AstraZeneca will be hosting a second oncology summit on June 17 in Gaithersburg, MD expanding to include some of the leading voices in the oncology space.

With a 30-year legacy in oncology, AstraZeneca has been a leader in developing innovative approaches to treat cancer, concentrating on those therapy areas where we believe we can make the greatest difference. It is our primary commitment to patients that is at the heart of everything we do. Join our conversation: #AZoncology.

On June 17, AstraZeneca will host an Oncology Summit with leading voices in the breast, lung, ovarian and thyroid cancer spaces. Join the conversation: #AZoncology

On June 17, AstraZeneca will host an Oncology Summit with leading voices in the breast, lung, ovarian and thyroid cancer spaces. Join the conversation: #AZoncology

3001314     Last Updated 6/14

AZ Sponsors Health Transformer Showcase at Health Datapalooza 2014

AstraZeneca understands the importance of staying on the cutting edge of technology as it relates to the healthcare industry. Earlier this month AstraZeneca attended Health Datapalooza 2014 in Washington D.C. This annual conference brings together leading healthcare organizations, academic institutions, government agencies, and individuals to share innovative ideas around the use of health data to improve patient outcomes. The jam packed three days were filled with insightful speeches, interactive events, and access to some of the most forward thinking minds in healthcare.

Through our partnership with Startup Health, an initiative that supports entrepreneurs in building sustainable health and wellness companies, AstraZeneca sponsored and hosted the Health Transformer Showcase. This invite-only sub-event gave 39 startups the chance to present one minute elevator pitches to a group of renowned investors and business leaders. The startups were split into five categories: Transparency and Care Access, Provider Solutions, Patient Engagement, Practice Workflows, and Genomics and Big Data. See a complete list of the startups that presented here.

Startup Health2aSome of the companies that stood out from the crowd included:


AdhereTech makes a patented smart pill bottle that can measure the amount of medication inside the bottle and alert patients when to take their pills, ultimately improving adherence.

Maxwell Health

Maxwell Health offers a SaaS platform that dramatically simplifies employee benefits for businesses and reduces the cost of benefits while also improving employee health.  Added benefits include a concierge service for every member enrolled, and a customizable wellness program.

Yingo Yango

Yingo Yango is a cloud-­based service, delivered to a customizable, white-label platform, that connects individuals to the health and wellness resources provided by their employers.


Caremerge provides a complete set of web and mobile communication and care-coordination solutions for senior living communities.

Tute Genomics

Tute Genomics is a web-based clinical genome interpretation engine that is robust, professional grade, lives in the cloud, and has the ability to analyze and annotate personal genomes in a rapid and cost-effective way.

Startup Health1a

Through our presence at the conference, AstraZeneca forged new relationships with innovative young companies that are transforming healthcare and are committed to goals that are in line with our mission and values.